Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 11/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 7/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 7/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 7/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 7/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 7/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748450 | 0.88 | PRKAB2 (0.48) | TDO2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL31748704 | 0.85 | PRKAG1 (0.47) | TDO2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL31748496 | 0.80 | PRKAB2 (0.61) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748384 | 0.79 | TDO2 (0.54) | TDO2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL31748356 | 0.73 | PRKAB2 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748607 | 0.73 | PRKAG1 (0.61) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748548 | 0.71 | PRKAB2 (0.41) | TDO2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL31748597 | 0.70 | IDO1 (0.38) | TDO2 | |
| SCHEMBL31748360 | 0.69 | PRKAB2 (0.61) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748414 | 0.68 | PRKAB2 (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | TDO2 4766/4885PRKAB2 1/4885PRKAG1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.